Dr Clyde Yancy: Redefine Greatness Through a Quest for Health Equity in Heart Failure
March 8th 2023Speaking at the 72nd American College of Cardiology Scientific Session in New Orleans on Sunday, Clyde W. Yancy, MD, MSc, the vice dean for diversity and inclusion at the Feinberg School of Medicine at Northwestern University, challenged the audience to rethink what success looks like in health care.
Read More
Results for the STELLAR trial, presented at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology, hit nearly every mark: patients taking sotatercept improved their performance on a 6-minute walk test by 40.8 meters, which was the primary end point, and achieved 8 of 9 secondary end points.
Read More
HALO Misses End Point, but Optimism Remains for Baxdrostat in Resistant Hypertension
March 5th 2023Baxdrostat is a highly selective aldosterone synthase inhibitor; phase 1 studies showed that the therapy caused a sustained, dose-dependent reduction in plasma aldosterone by more than 70% without reducing cortisol.
Read More
Bempedoic Acid, Approved to Treat LDL Cholesterol, Cuts Risk of Major CV Events by 13%
March 4th 2023Results from the CLEAR Outcomes trial were presented today at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology. Plans for a broader label are in the works.
Read More
Dr Deepak Bhatt Discusses Results From the ENTRIGUE Trial
March 2nd 2023Deepak L. Bhatt, MD, MPH, Icahn School of Medicine at Mount Sinai, has multiple presentations during the upcoming American College of Cardiology Scientific Sessions, including additional phase 2 results from the ENTRIGUE trial for pegozafermin in severe hypertriglyceridemia.
Read More
ACCESS Tests Effect of Eliminating Co-pay on CV Outcomes
March 1st 2023Braden Manns, MD, MSc, a nephrologist and health economics researcher at the University of Calgary in Canada, will present the results of a randomized trial evaluating the impact of removing co-payments for drugs that treat chronic conditions on cardiovascular outcomes during the American College of Cardiology Scientific Sessions in New Orleans, Louisiana, on Sunday, March 5.
Read More
Dr Crystal Zhou Discusses Incorporating Pharmacists Into the Cardiology Care Team
April 5th 2022Patients who cardiologists see once every few months are getting handed over to pharmacists who can monitor them more frequently and get them to their goals, said Crystal Zhou, PharmD, assistant professor of Clinical Pharmacy at the University of California, San Francisco (UCSF).
Read More
Consider the Whole Patient When Choosing Treatment, Says Dr Marc Bonaca
April 5th 2022Patients often have comorbidities that make it important to consider them holistically and not bucket them into one disease state, and the findings on rivaroxaban show broad benefits and a favorable risk-benefit profile, said Marc Bonaca, MD, MPH, of CPC Clinical Research and CPC Community Health and the University of Colorado School of Medicine.
Read More
Dr Raul Santos Explains the Benefits of Treating Children With FH Early
April 4th 2022Treating children with familial hypercholesterolemia (FH) early can help reduce progression of atherosclerosis without adverse events related to growth and development, said Raul Santos, MD, PhD, director, Lipid Clinic at the Heart Institute, and associate professor, University of São Paulo Medical School, Brazil.
Read More
Dr Dipti Itchhaporia Highlights Aspects of Virtual Care Here to Stay
April 4th 2022Even as virtual care has dropped from the peaks at the beginning of the pandemic, some aspects of it will not go away in cardiology care, said Dipti Itchhaporia, MD, FACC, the 70th president of the American College of Cardiology.
Read More
EMPULSE: Empagliflozin Yields QOL Benefits in Patients Hospitalized for Acute HF
April 4th 2022Patients hospitalized for acute heart failure and prescribed empagliflozin saw improvements in quality of life at 15 and 90 days post-discharge. The study may make the case for prescribing SGLT2 inhibitors before patients leave the hospital.
Read More
Dr Pam Taub Emphasizes Lower Is Better for LDL Cholesterol Levels
April 3rd 2022There is some confusion about the differences between the European and American guidelines on lowering low-density lipoprotein (LDL) cholesterol, but it’s clear that lower is better, said Pam Taub, MD, FACC, professor of medicine, Division of Cardiovascular Medicine, UC San Diego School of Medicine.
Read More
SCORED: Sotagliflozin Leads to Reductions in CV Death, MI, Stroke Regardless of CVD Presence
April 2nd 2022Additional analyses from the SCORED trial further highlight sotagliflozin's benefits among patients with type 2 diabetes and chronic kidney disease, regardless of cardiovascular disease presence.
Read More
Dr Milind Desai Addresses Late-breaking VALOR-HCM Trial Findings at ACC 2022
April 2nd 2022Milind Desai, MD, MBA, director of the Center for Hypertrophic Cardiomyopathy and medical director of the Center for Aortic Diseases, Cleveland Clinic, speaks on therapeutic implications of the VALOR-HCM late-breaking clinical trial findings presented Saturday at the American College of Cardiology's 71st Scientific Session.
Read More
Abstracts Outline Costs of Heart Health in US, Benefits of Protective Measures
April 1st 2022New research presented at the American College of Cardiology's 71st Annual Scientific Session & Expo highlights the high costs of heart failure in the United States and the benefits of healthy eating and exercise as preventive measures.
Read More
Dr Orly Vardeny Previews Session on Barriers to Novel Treatment Access at ACC 2022
March 31st 2022Orly Vardeny, PharmD, MS, core investigator, Center for Care Delivery and Outcomes Research, and associate professor of Medicine, University of Minnesota Medical School, discusses key barriers to access of novel therapies and what sessions she’s looking forward to during the American College of Cardiology's (ACC) 71st Annual Scientific Session.
Read More
Hospital Quality Program for Heart Failure Patients Fails to Improve Outcomes
May 18th 2021The study presented during the American College of Cardiology's 70th Scientific Session called for one group of hospitals to receive special audits and guidance aimed at improving care of patients with heart failure.
Read More
Matching Right Patients to Right Drugs Is Key With New Entrants to Heart Failure Market
May 18th 2021Sessions, posters, and late-breaking trials at the American College of Cardiology’s 70th Scientific Session offer updates on vericiguat, SGLT2 inhibitors, sacubitril/valsartan, and heart failure therapies still in the pipeline.
Read More
Dr Deepak L. Bhatt: Sotagliflozin Shows Promise for Patients With Heart Failure, Diabetes
May 17th 2021There was consistent, and significant, benefit across all categories of ejection fraction—preserved, reduced, and midrange—but especially among those with preserved ejection fraction, noted Deepak L. Bhatt, MD, MPH, Brigham and Women’s Hospital Heart & Vascular Center.
Read More
Dr Mariana Garcia: Nontraditional Risk Factors Can Affect CV Health in Younger Adults
May 17th 2021There is a possible link between psychological distress and inflammatory markers in younger patients with a history of cardiovascular (CV) disease, specifically myocardial infarction, said Mariana Garcia, MD, cardiology fellow at Emory University.
Read More
Dr Clyde Yancy: Heart Failure With Preserved Ejection Fraction Is Not One Disease
May 16th 2021Heart failure is clearly syndromic, with several phenotypes, so it will remain challenging to reconcile patient to therapy until these unique phenotypes can be studied, stated Clyde W. Yancy, MD, MSc, of Northwestern University’s Feinberg School of Medicine.
Read More